Introduction {#s1}
============

Inflammatory Bowel Disease (IBD) encompasses a group of disorders, including Crohn\'s disease (CD) and ulcerative colitis (UC), characterized by chronic relapsing inflammation of the gastrointestinal (GI) tract. IBD affects as many as 3 million Americans, most of whom are diagnosed before age 35 ([@B1]). These disorders are chronic, life-long conditions that can be treated, but currently do not have a cure. Chronic abdominal pain is one of the major reasons individuals with IBD seek medical attention ([@B2]) and is described in up to 70% of patients at the onset or during exacerbations of the disease ([@B3]). The inflammation associated with IBD is considered to be a primary driver of this pain, as pro-inflammatory mediators sensitize extrinsic sensory neurons that project to the gut.

In some instances, however, the lack of abdominal pain in IBD can also pose different but significant challenges. Individuals with so-called hypoalgesic and/or "silent" IBD have grossly evident intestinal inflammatory changes that do not produce significantly painful or other noxious sensations. It has been increasingly recognized that symptom-based assessment tools can be relatively insensitive for accurately assessing IBD activity ([@B4]). Various estimates have suggested that a third or more of IBD patients with active disease will be asymptomatic ([@B5], [@B6]). This is important considering that individuals with "silent" IBD are less likely to seek appropriate medical attention and more likely to develop complications (including strictures, fistulae, and abscesses) and ultimately incur major healthcare costs, including hospitalization ([@B6]).

Voltage-gated sodium channels (VGSC\'s) appear to play an important role in visceral pain perception ([@B7]). In particular, three VGSC\'s (Na~v~1.7, Na~v~1.8, and Na~v~1.9) have recently been implicated as primary mediators of visceral nociceptive function, including that associated with the gastrointestinal tract. Investigations incorporating retrograde labeling techniques have demonstrated the presence of these channels in nociceptive neurons innervating the stomach, small intestine, and colon ([@B7]--[@B12]). The electrophysiological profile of these cells suggests that Na~v~1.8 is particularly important for their normal function ([@B12]--[@B14]). In support of this idea, studies assessing nociceptive response in animal models utilizing chemically induced colitis successfully attenuate the associated pain using either therapeutics ([@B15]) or genetic knock-outs that target Na~v~1.8 ([@B16]). We hypothesized that genetic variants inducing a "loss-of-function" in one or more of the genes associated with Na~V~1.7, Na~V~1.8, or Na~V~1.9 (SCN9A, SCN10A, and SCN11A, respectively) in IBD patients would result in anti-nociceptive function and diminished abdominal pain perception.

Materials and methods {#s2}
=====================

Study participant selection
---------------------------

We obtained relevant clinical and patient survey data from individuals who had consented to take part in a prospective IBD natural history registry and tissue biorepository associated with the IBD Center at Penn State Hershey Medical Center \[approved by the Penn State College of Medicine Institutional Review Board (PRAMSHY98-057)\] and who had undergone a colonoscopy between October 1, 2015 and January 31, 2017.

### Inclusion criteria

We included patients with established diagnoses of IBD who had (1) undergone a colonoscopy, (2) completed a pain questionnaire (see below) at the time of endoscopy, and (3) had provided a blood sample as part of their participation in the registry and biorepository. In addition, IBD study participants had to meet the following criteria: (1) age ≥ 18 years; (2) established diagnosis of IBD (either Crohn\'s Disease or Ulcerative Colitis, based upon standard clinical criteria incorporating historical, laboratory, endoscopic, and histological evaluation); (3) no coexisting condition that could explain abdominal pain, including pregnancy, trauma, malignancy, infection, or non-IBD associated inflammatory disorder. We also included a cohort of healthy adult (age ≥ 18 years) control patients who had no documented history of chronic gastrointestinal illness or known pain disorder.

### Exclusion criteria

IBD patients were excluded if they had an indeterminate form of IBD, microscopic colitis, inflammatory enteritis or colitis not associated with IBD or had not provided information about pain at or within 1 month of the colonoscopy. Patients were also excluded if they had undergone a total colectomy or proctocolectomy at any time or any intra-abdominal surgery within the calendar year prior to the time of the study encounter. Healthy controls were excluded if they had a history of chronic gastrointestinal disease or acute or chronic abdominal pain or other pain disorder.

Characterization of intestinal inflammatory status and complications
--------------------------------------------------------------------

Disease severity and location were recorded for each IBD study participant utilizing contemporary endoscopic, histologic, and radiologic information. CD and UC location and phenotype were classified according to the Montreal Classification system ([@B17]). The severity of UC disease activity was determined based upon the appearance of the mucosa at the time of endoscopy and characterized using the Mayo Clinic endoscopy sub-score ([@B18]). The severity of CD was also determined by appearance at endoscopy using the Crohn\'s Disease Simple Endoscopic Score (SES-CD) ([@B18]). Both the Mayo score and the SES-CD are based upon a Likert-type scale ranging from 0 to 3 (with 0 = inactive, 1 = mild activity, 2 = moderate activity and 3 = severe activity). All complications described were intra-abdominal/luminal in nature (e.g., abscesses and fistulae described were not perianal phenomena).

Abdominal pain assessment
-------------------------

Abdominal pain ratings were based primarily on responses to the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), that asks patients to grade pain on a frequency-based inverse Likert scale ("How often over the past 2 weeks have you been troubled by pain in the abdomen?"), with 1 representing pain "all of the time" and 7 representing pain "none of the time" ([@B19]). We also obtained information about pain severity using responses to an ulcerative colitis activity index survey, that asks about the severity of abdominal pain (with potential responses including 0 ("no abdominal pain"), 1 ("mild"), 2 ("moderate") and 3 ("severe"). As abdominal pain frequency and intensity scores correlated with one another (*r* = −0.7, *p* \< 0.001), we operationally defined presence of clinically meaningful abdominal pain as SIBDQ pain ratings of ≤ 5 (with 5 defined as "a little of the time").

Determination of study cohorts
------------------------------

There were three cohorts evaluated during this study: (1) IBD patients with active disease who had an SIBDQ pain score of \>5 (describing "hardly any" to "no" abdominal pain) (i.e., active disease with no pain (ANP) or "hypoalgesic IBD"), (2) all other IBD patients, and (3) healthy control patients. Basic demographic and disease characteristics of each group can be found in Table [1](#T1){ref-type="table"}. Of note, all patients identified as having active disease had a Mayo or SES-CD score of 2 or greater. As described above, all patients with an SIBDQ pain score of ≤ 5 were defined as having abdominal pain.

###### 

Study participant demographic and disease characteristics.

                              **"Hypoalgesic IBD" (*****n*** = **41)**   **Other IBD (*****n*** = **80)**   **Controls (*n* = 86)**   ***p*****-value**                  
  --------------------------- ------------------------------------------ ---------------------------------- ------------------------- ------------------- -- ----------- -----------
  Age (years)                 41.8 ± 2.6                                 41.7 ± 1.5                         63.3 ± 1.1                \< 0.0001                          
  Gender (female:male)        15:26                                      43:37                              42:44                     0.20                               
  Disease type (CD:UC)        25:16                                      52:28                              --                        0.69                               
  Disease location            [CD]{.ul}                                  [UC]{.ul}                          [CD]{.ul}                 [UC]{.ul}              [CD]{.ul}   [UC]{.ul}
  (Montreal classification)   L1: 4                                      E1: 0                              L1: 7                     E1: 0                  0.74        1
                              L2: 5                                      E2: 4                              L2: 14                    E2: 10                 0.58        0.52
                              L3: 16                                     E3: 12                             L3: 31                    E3: 18                 0.99        0.52
                              L4: 0                                                                         L4: 0                                            1           
  Disease duration (years)    11.5 ± 1.3                                 13.4 ± 1.0                         --                        0.28                               
  History of stricture        15                                         8                                  --                        0.001                              
  History of fistula          8                                          3                                  --                        0.007                              
  History of abscess          9                                          3                                  --                        0.003                              
  History of colon cancer     1                                          0                                  --                        0.34                               

*Using the Montreal Classification system for localizing disease activity, for Crohn\'s disease, L1, terminal ileum; L2, colon; L3, ileocolonic and L4, upper gastrointestinal tract; while for ulcerative colitis; E1, proctitis; E2, left sided colitis, and E3, pan-colitis. IBD, inflammatory bowel disease; CD, Crohn\'s Disease; UC, ulcerative colitis*.

DNA isolation
-------------

High-quality genomic DNA was isolated from whole blood using silica-based spin columns (QIAmp DNeasy Blood & Tissue Kit, Qiagen, Hilden, Germany). Spectrophotometry was used to quantify DNA and the quality of the isolated material was evaluated with an Agilent Bioanalyzer.

Custom target capture sequencing and analysis
---------------------------------------------

The custom capture oligo set was designed by the SureDesign platform from Agilent Technologies (SureSelectXT Custom Capture Oligo) against *SCN9A, SCN10A*, and *SCN11A*. This set was specifically designed to capture all exons, the proximal promoter sequence, as well as limited intron sequences and untranslated regions near exons. The target-captured sequencing libraries were constructed using the KAPA LTP Library Preparation Kit (Kapa Biosystems, Inc., Wilmington, MA) combined with a SureSelectXT Reagent Kit (Agilent Technologies), and sequenced on an Illumina Hiseq 2500 sequencer (Illumina, Inc, San Diego, CA) at read length of paired-end 2 × 100 bp. Targeted exome sequencing was performed on an initial cohort of 46 IBD patients that included a mixture of individuals with and without inflammation and abdominal pain. Generated reads were aligned with the GRCh37 human reference genome using the Burrows-Wheeler alignment ([@B20]). Variant detection and analysis were performed using the GATK Best Practice for germline SNP/indel finding workflow (Broad Institute). ANNOVAR software ([@B21]) was used to annotate the variants and identify synonymous, non-synonymous, and deleterious variants for further analysis.

TaqMan SNP genotyping
---------------------

For rigor and reproducibility, genotype analysis of all 46 IBD samples described above, along with samples from an additional 75 IBD patients (121 total) and 86 healthy control patients, was performed with commercially available TaqMan assays using the OpenArray platform on a QuantStudio 12K Flex instrument (Thermo Fisher Scientific; formerly Life Technologies, Grand Island, NY). This analysis was performed on the single nucleotide polymorphisms (SNPs) identified in the original cohort of 46 IBD patients that achieved a *p* value of 0.1 or less and included the polymorphisms rs4073113 (*p* = 0.009), rs4234134 (*p* = 0.057), and rs6795970 (*p* = 0.096). Twenty nanograms of genomic DNA were amplified per the manufacturer\'s directions and scaled to a total volume of 5 μL in an Applied Biosystems® Veriti® 384-well thermal cycler for each of the above assay IDs.

Statistical analysis
--------------------

Patients\' baseline and clinical characteristics were summarized as descriptive statistics. Chi-squared or Fisher\'s exact test was used to compare categorical variables between groups, while independent *t*-test or one-way ANOVA was used to compare continuous variables between groups as appropriate. Fisher\'s exact test was used to analyze the tables of genotypic and allelic frequencies. Only one polymorphism identified from the targeted exome sequencing performed on the original 46-person IBD cohort approached a significantly higher incidence in the hypoalgesic IBD cohort (rs6795970). This variant was also the only exonic polymorphism that encoded a non-synonymous amino acid change and this SNP has previously been associated with hyposensitivity to somatosensory pain stimulation ([@B22]). As a result, we decided to focus the remainder of our analysis primarily on this variant. Data analyses were performed using GraphPad Prism v.7.0a (La Jolla, CA) or R 3.4.1 (R Core Team for Statistical Computing, Vienna, Austria, <http://www.R-project.org>). All *p* values of \< 0.05 were considered statistically significant.

Ethical considerations
----------------------

All of the work described herein was performed following the guidelines set forth by and with the permission of the Penn State College of Medicine Institutional Review Board. All study participants gave written informed consent in accordance with the Declaration of Helsinki.

Results {#s3}
=======

Study participant characteristics
---------------------------------

We identified and evaluated 121 IBD patients (41 hypoalgesic IBD, 80 other IBD) and 86 healthy controls (Table [1](#T1){ref-type="table"}). The IBD cohorts had similar mean ages (and mean disease durations) while the healthy controls were significantly older (*p* \< 0.0001). Each cohort had similar gender distributions. The IBD cohorts were each composed primarily of CD patients, in statistically similar proportions. There were no significant differences in disease location \[using the Montreal Classification system ([@B17])\] in either the CD or UC patients when comparing the hypoalgesic and other IBD cohorts. Of note, the hypoalgesic IBD cohort was found to have significantly more strictures (*p* = 0.001), fistulae (*p* = 0.007), and abscesses (*p* = 0.003) when compared to other IBD cohort.

Exon sequences of SCN9A, SCN10A, and SCN11A from targeted exome next-generation sequencing
------------------------------------------------------------------------------------------

As described above, DNA samples from 45 IBD patients were initially subjected to targeted exome next-generation sequencing. Overall, the mean read depth for the targeted exome sequence was 85x, with 79% of the exome covered at least 59x, and 87% of the targeted sequence covered at a read depth of 50x or more. A total of 49 exonic, single nucleotide polymorphisms (SNPs) were observed in the targeted deep sequencing of the 45 IBD patients as called using the GATK Best Practice pipeline (Table [2](#T2){ref-type="table"}). SCN9A demonstrated 14 SNPs, SCN10A had 22 SNPs, and SCN11A had 13 SNPs. In order to confirm the findings of the targeted exome sequencing, three SNPs (1 in SCN10A and 2 in SCN11A, all in bold in Table [3](#T3){ref-type="table"}) were analyzed by TaqMan in all 207 study participants. The results matched 100% to the targeted exome sequencing results in the original 45 patients.

###### 

Single nucleotide polymorphisms (SNPs) identified for the SCN9A, SCN10A, and SCN11A genes in our initial study population.

  **SCN9A**     **SCN10A**   **SCN11A**                                                  
  ------------- ------------ ------------ ------------- --- ---------- ------------- --- ----------
  rs149207258   2            166199827    rs6790627     3   38748833   rs4234134     3   38887970
  rs4303728     2            166199918    rs11711062    3   38753732   rs4234133     3   38888021
  rs188336294   2            166226651    rs6771157     3   38763863   rs192005503   3   38888085
  rs6746030     2            166242648    rs12632942    3   38764998   rs4640498     3   38888227
  rs74401238    2            166251875    rs6795970     3   38766675   rs72869687    3   38888735
  rs41268673    2            166284599    rs6791171     3   38766701   rs62244134    3   38888764
  rs58022607    2            166286469    rs73062575    3   38766760   rs78953918    3   38892069
  rs201531206   2            166286540    rs59468016    3   38768247   rs148945365   3   38908944
  rs6747673     2            166288464    rs57326399    3   38768300   rs33985936    3   38936134
  rs13402180    2            166288485    rs7374804     3   38768334   rs4073113     3   38945560
  rs58465962    2            166288596    rsN/A         3   38768347   rs78812474    3   38991598
  rs13414203    2            166288632    rsN/A         3   38768353   rsN/A         3   38991922
  rs9646771     2            166306533    rsN/A         3   38768354   rs73068589    3   38992033
  rs6432901     2            166311583    rsN/A         3   38768355                     
                                          rsN/A         3   38768362                     
                                          rs146028829   3   38770198                     
                                          rs7630989     3   38793940                     
                                          rs7617919     3   38793989                     
                                          rs62244070    3   38798171                     
                                          rsN/A         3   38802773                     
                                          rs74717885    3   38805069                     
                                          rs34314583    3   38835457                     

###### 

Relative frequency of SCN9A, SCN10A, and SCN11A SNPs in "Hypoalgesic IBD" compared to other IBD patients.

  **ID**        **Gene**   **Residue**   **Major**   **Minor**   **"Hypoalgesic IBD"**   **"Other IBD"**   **Odds**   ***P*-value**
  ------------- ---------- ------------- ----------- ----------- ----------------------- ----------------- ---------- ---------------
  *rs4073113*   *SCN11A*   *C546C\**     *A*         *G*         *84.8*                  *59.1*            *3.8571*   *0.0093*
  rs4234134     SCN11A     3\' UTR       T           A           39.1                    61.4              0.4048     0.0571
  *rs6795970*   *SCN10A*   *V1073A\**    *A*         *G*         *54.3*                  *36.4*            *2.0833*   *0.0958*
  rs73062575    SCN10A     P1044T        G           T           0.0                     6.8               0.1275     0.1127
  rs4234133     SCN11A     3\' UTR       T           C           39.1                    56.8              0.4886     0.1391
  rs6791171     SCN10A     T1063T        C           T           10.9                    2.3               5.2439     0.2035
  rs41268673    SCN9A      P610T         G           T           0.0                     4.5               0.1828     0.2362
  rs41268673    SCN9A      P610T         G           T           0.0                     4.5               0.1828     0.2362
  rs78953918    SCN11A     T1410T        C           T           0.0                     4.5               0.1828     0.2362
  rs74717885    SCN10A     I206M         T           C           6.5                     0.0               7.1609     0.2419
  rs: N/A       SCN11A     3\'UTR        C           T           0.0                     0.0               0.4889     0.3118
  rs62244134    SCN11A     Y1599Y        G           A           15.2                    6.8               2.4530     0.3161
  rs7630989     SCN10A     S509P         A           G           8.7                     2.3               4.0952     0.3614
  rs6746030     SCN9A      R1150W        A           G           80.4                    88.6              0.5271     0.3856
  rs33985936    SCN11A     V909I         C           T           19.6                    27.3              0.6486     0.4589
  rs7374804     SCN10A     K950K         T           C           13.0                    6.8               2.0500     0.4856
  rs11711062    SCN10A     S1336T        A           T           0.0                     2.3               0.3118     0.4889
  rs: N/A       SCN10A     L265V         G           C           0.0                     2.3               0.3118     0.4889
  rs13414203    SCN9A      A373A         A           G           28.3                    36.4              0.6894     0.5002
  rs9646771     SCN9A      P148P         T           C           56.5                    63.6              0.7429     0.5250
  rs73068589    SCN11A     5\' UTR       C           A           10.9                    15.9              0.6446     0.5464
  rs6790627     SCN10A     K1440K        T           C           13.0                    18.2              0.6750     0.5693
  rs59468016    SCN10A     G979G         G           A           21.7                    15.9              1.4683     0.5931
  rs13402180    SCN9A      E422E         T           C           28.3                    34.1              0.7616     0.6503
  rs6747673     SCN9A      R429R         A           T           39.1                    45.5              0.7714     0.6699
  rs149207258   SCN9A      V1593V        C           A           4.3                     6.8               0.6212     0.6733
  rs78812474    SCN11A     R86R          G           T           4.3                     6.8               0.6212     0.6733
  rs7617919     SCN10A     L492L         G           A           17.4                    13.6              1.3333     0.7731
  rs6771157     SCN10A     T1130T        G           C           19.6                    15.9              1.2857     0.7846
  rs12632942    SCN10A     L1091P        A           G           19.6                    15.9              1.2857     0.7846
  rs57326399    SCN10A     I962V         T           C           21.7                    18.2              1.2500     0.7939
  rs6432901     SCN9A      Q58Q          C           T           56.5                    59.1              0.9000     0.8338
  rs62244070    SCN10A     E428E         C           T           17.4                    15.9              1.1128     1.0000
  rs188336294   SCN9A      V1427V        G           A           2.2                     0.0               2.9341     1.0000
  rs74401238    SCN9A      R1110Q        C           T           2.2                     0.0               2.9341     1.0000
  rs58022607    SCN9A      S490N         C           T           2.2                     0.0               2.9341     1.0000
  rs201531206   SCN9A      S466S         G           A           2.2                     0.0               2.9341     1.0000
  rs58465962    SCN9A      V385V         C           A           2.2                     0.0               2.9341     1.0000
  rs: N/A       SCN10A     E848G         T           C           2.2                     2.3               0.9556     1.0000
  rs: N/A       SCN10A     E846Q         T           A           2.2                     2.3               0.9556     1.0000
  rs: N/A       SCN10A     E846V         C           G           2.2                     2.3               0.9556     1.0000

*Asterisks denote SNPs that were confirmed by Taqman PCR genotyping. Of note, the deep sequencing and PCR genotyping were 100% concordant*.

SNP association analysis: comparing "hypoalgesic IBD" patients with other IBD patients
--------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} presents the odds ratios for the 49 SNPs observed in the deep sequencing of all the IBD patients (arranged from most statistically significant to least). Three SNPs \[rs4073113 (*p* = 0.009), rs4234134 (*p* = 0.057), and rs6795970 (*p* = 0.096)\] demonstrated differential expression in "hypoalgesic IBD" patients when compared to all other IBD patients exhibiting a *p* value of 0.1 or less (Fisher\'s exact test).

The rs6795970 polymorphism produces a non-synonymous amino acid change (alanine at amino acid 1073 to valine in *SCN10A*; A1073V). This functional polymorphism was therefore examined in all 121 IBD patients. Homozygotic frequency for the rs6795970 polymorphism was significantly higher in the hypoalgesic IBD cohort when compared to the other IBD patients (*p* = 0.01) (Table [4](#T4){ref-type="table"}). This was not the case when hypoalgesic IBD patients were compared to healthy controls (Table [5](#T5){ref-type="table"}). Of note, no differences in homozygotic frequency were found for the other SNP described above (rs4073113) or the other SNPs outlined in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} when comparing the three study cohorts (hypoalgesic IBD, other IBD or controls).

###### 

Genotypic and allelic frequencies of the SCN10A polymorphism, rs6795970 in Hypoalgesic IBD vs. "Other IBD" patients.

                                                   **"Hypoalgesic IBD"**    **Other IBD**             ***p*-value**
  ------------------------------------------------ ------------------------ ------------------------- ---------------
  **Genotypic frequency (SCN10A, Na**~v~**1.8)**   **(*****n*** = **41)**   **(*****n*** = **80)**    
  A/A (1073Val/Val)                                19 (46%)                 18 (22%)                  0.01
  A/G (1073Val/Ala)                                14 (34%)                 45 (55%)                  
  G/G (1073Ala/Ala)                                8 (20%)                  17 (23%)                  
  **Allelic frequency**                            **(*****n*** = **82)**   **(*****n*** = **160)**   
  A (valine)                                       52 (63%)                 91 (57%)                  0.34
  G (alanine)                                      30 (37%)                 69 (43%)                  

*Frequencies are listed as number of subjects (% of genotypic or allelic total). The homozygous genotype (A/A) for the rs6795970 polymorphism was significantly more common in the Hypoalgesic IBD group (p = 0.01, Fisher\'s Exact Test). The allelic frequency of this polymorphism was not more common in the Hypoalgesic IBD group (p = 0.34, Fisher\'s Exact Test). G, wild type; A, rs6795970 polymorphism (c.3218G \> A). Notably, according to the 1,000 Genomes sequencing project, the A allele is present at a frequency of 29% of the Caucasian population (the primary demographic of this study group)*.

###### 

Genotypic and allelic frequencies of the SCN10A polymorphism, rs6795970 in Hypoalgesic IBD vs. Healthy Control patients.

                                                   **"Hypoalgesic IBD"**    **Healthy Controls**      ***p*-value**
  ------------------------------------------------ ------------------------ ------------------------- ---------------
  **Genotypic frequency (SCN10A, Na**~v~**1.8)**   **(*****n*** = **41)**   **(*****n*** = **86)**    
  A/A (1073^Val/Val^)                              19 (46%)                 30 (35%)                  0.25
  A/G (1073^Val/Ala^)                              14 (34%)                 40 (47%)                  
  G/G (1073^Ala/Ala^)                              8 (20%)                  16 (18%)                  
  **Allelic frequency**                            **(*****n*** = **82)**   **(*****n*** = **172)**   
  A (valine)                                       52 (63%)                 100 (58%)                 0.49
  G (alanine)                                      30 (37%)                 72 (42%)                  

*Frequencies are listed as number of subjects (% of genotypic or allelic total). The homozygous genotype (A/A) for the rs6795970 polymorphism was not significantly different between the cohorts (p = 0.25, Fisher\'s Exact Test). Allelic frequency of this polymorphism was also not significantly different (p = 0.49, Fisher\'s Exact Test). G, wild type; A, rs6795970 polymorphism (c.3218G \> A). Of note, according to the 1,000 Genomes sequencing project, The "A" allele is present at a frequency of 29% of the Caucasian population (the primary demographic of this study group)*.

Discussion {#s4}
==========

This investigation of three VGSC genes, SCN9A, SCN10A, and SCN11A, demonstrated that "hypoalgesic IBD" patients had a statistically higher prevalence of homozygosity for one SNP: rs6795970 (SCN10A). This polymorphism encodes a non-synonymous amino acid substitution (alanine at amino acid 1073 to valine in *SCN10A*; A1073V). As indicated above, this SNP demonstrated an increased homozygotic frequency in the "hypoalgesic IBD" cohort compared to other IBD patients. This finding is significant for a number of reasons. Although other studies have provided evidence for links between specific SNPs and syndromes associated with visceral hypersensitivity (including irritable bowel syndrome \[Na~V~1.5, ([@B23])\] and functional dyspepsia \[Na~V~1.8, ([@B24])\], this is the first demonstration of an association between an abdominal pain phenotype in IBD and a particular genetic variant. This is also one of the first SNPs associated with diminished pain experience in a gastrointestinal disorder. It is important to note that the significant association described above is specifically with homozygosity for rs6795970 (that is, for individuals that presumably only have the polymorphic channel). Heterozygotes do not display a variant frequency, suggesting that one "wild-type" copy is sufficient to protect individuals from the associated physiological alterations that result in hypoalgesic and/or "silent" IBD.

There is growing evidence that this particular polymorphism (rs6795970) and the associated Na~V~1.8 channel have significant influence on visceral pain perception. The *SCN10A* gene encodes the alpha subunit of Na~V~1.8 ([@B22], [@B25], [@B26]). This channel is predominantly expressed in the periphery and, as previously indicated, appears to play a critical role in pain transmission. A functional assessment of this polymorphism by Duan and colleagues revealed that this same genetic variant (rs6795970) results in altered electrophysiological function of the Nav1.8 channel and higher thresholds for mechanical pain in a discovery cohort ([@B22]). Functional assessments have shown that the minor allele of rs6795970 (valine-1073) shifts sodium channel activation, resulting in reduced repetitive firing of dorsal root ganglion neurons, thereby lowering mechanical pain sensitivity ([@B23]). This is the first study in humans to demonstrate a link between a genetic variant of Na~V~1.8 and intestinal pain perception in the setting of IBD (or any other gastrointestinal disorder). This is an important finding that provides key insights regarding visceral nociceptive physiology and new potential diagnostic and therapeutic targets to consider in patients with disorders of abdominal pain perception.

We are confident in the results of this investigation for several reasons. Our study determined current IBD disease activity through direct endoscopic evaluation of the intestinal mucosa and coupled this information with contemporary validated survey results relating to patient abdominal pain experience. We performed a comprehensive evaluation and analysis of the three VGSC genes of interest (SCN9A, SCN10A, and SCN11A) and compared all of the resultant SNPs (totaling 49 independent polymorphisms) among the study cohorts. The initial genetic findings were "double-checked" by Taqman PCR and additional samples were evaluated using the same methodology. These results make us feel more assured of the findings and the significant influence that the rs6795970 SNP has in this context, particularly because it was the only variant encoding a non-synonymous amino acid change that was found to be significantly different in prevalence among any of the study cohorts.

Potential limitations of this study include the relatively small sample size and the fact that it was performed using individuals from a single medical center. It will be important to independently validate the results of this investigation with larger numbers of the same patient cohorts. It would also be informative to perform this analysis in other conditions associated with chronic abdominal pain, including irritable bowel syndrome. Our determination of hypoalgesic IBD was also based upon the survey responses and colonoscopic findings from one clinical encounter. It would be useful to determine how consistent these findings (and the study cohorts) were between different time points. Additionally, our cohort of interest focused only on abdominal pain experience and did not include consideration of other symptoms frequently associated with IBD, such as diarrhea, bleeding, and bloating. We utilized this approach in order to minimize potential confounding that could occur in the process of interpreting our data. However, future analyses incorporating individuals lacking the additional symptoms described above could provide a more complete understanding of the so-called "silent" IBD phenotype, which has been associated with lack of perception and/or reporting of any symptom that could be associated with this disorder. The mean allelic frequency of the rs6795970 SNP in our total cohort was \~59%, which is significantly higher than that previously reported \[e.g., 1000 Genomes Project MAF = 29% ([@B27], [@B28])\] suggesting a potential founder\'s effect in our population (though this should not impact the relative differences in allelic or genotypic frequency found in this study). While we focused on the non-synonymous polymorphism, rs6795970, it is possible that the synonymous and untranslated region variants described above could also play a role in visceral pain perception, for example through differential codon usage or alteration of mRNA levels. Additionally, we used a mixed population of CD and UC patients. These conditions have varied potential mechanisms for inducing chronic abdominal pain that may not necessarily overlap neatly with one another and there is certainly reason to investigate larger, adequately powered cohorts of both CD and UC in this context. Finally, although validated surveys were utilized to provide information about patient abdominal pain experience, there was no objective measure of visceral nociceptive perception.

Despite these drawbacks, we believe the results of this study provide compelling evidence that Na~V~1.8 is important to visceral nociceptive function, particularly in the setting of IBD. In addition to confirming this concept in a larger population of IBD patients, it will also be important to evaluate healthy control cohorts in addition to other gastrointestinal conditions associated with alterations in visceral sensation (e.g., irritable bowel syndrome) to determine whether the impact of this channel and the genetic variant described above is limited to inflammatory conditions of the gut. It will also be important to further evaluate the relationship between the rs6795970 polymorphism, and Na~V~1.8 function in general, and visceral pain perception through mechanistic studies incorporating targeted genetic changes and objective measures of pain response (e.g., visceromotor response in animal knock-in models).

If the studies described above further substantiate the link between Na~V~1.8 and pain perception in IBD (and potentially other gut disorders associated with chronic abdominal pain), this will represent a novel, new target to help identify patients at higher risk of major disease-associated complications. It could also serve as a new model to help develop less toxic pain therapies in patients with chronic abdominal pain. This could help to minimize the use of other frequently used medication types associated with increased morbidity (e.g., NSAID\'s, opiates) while also more intelligently targeting the sensory systems associated with the pain, thereby reducing the use of high cost healthcare resources (e.g., emergency room visits, imaging, surgery) in the name of evaluating or treating chronic abdominal pain.
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